 Cantor Fitzgerald has initiated coverage of RedHill Biopharma Ltd NASDAQ:RDHL with an Overweight rating and a 22 price target, an upside of approximately 115. Redhill is focused on the development and commercialization of several interesting drugs, primarily focused on gastrointestinal and infectious diseases, analyst Brandon Folkes tells investors. 